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The application of stem cells as a therapy for degenerative disease holds great promise. Substantial evidence suggests that stem cell 
derived exosomes are a novel cell‑free therapy for the corresponding cells. Exosomes are less complex as compared to their parental 
cells, due to the fewer number of membrane proteins. In addition, the smaller size and lower risk of immunogenicity makes exosomes 
potentially safe therapeutic nano‑carriers. A large number of ongoing research studies are focused on characterizing exosomes that 
were derived from different sources, for their potential use in various therapeutic applications. In the present study, we focused on 
characterizing human amniotic fluid stem cell derived exosomes for future therapeutic applications, such as paracrine therapy/nano 
carrier. In addition, we characterized exosomes derived from SH‑SY5Y and BE(2)‑M17 cells, which are a known neuronal model, for 
further characteristic analyses of neuronal differentiation and neurobiology. Finally, we compared various exosome isolation techniques 
and procedures and evaluated exosome yield.
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INTRODUCTION
Regenerative medicine has burgeoned, largely due 
to recent advances in the field of stem cell transplan‑
tation. In particular, advances in stem cell transplan‑
tation allow for the replacement of damaged tissues 
with autologous or allogeneic stem cells derived from 
adipose, blood, bone, and brain tissue, to facilitate the 
regeneration of damaged or lost tissues. This is in con‑
trast to the only option 20 years ago, which involved 
grafting the whole tissue, such as bone marrow (Vish‑
nubhatla et al., 2014). Despite the remarkable results 
reported so far from the early phase trials of stem cell 
therapy (Matsa et al., 2014), it should be noted that the 
therapeutic benefits cannot be necessarily attributed 
to stem cells (Hicks et al., 2013). Indeed, recent stud‑
ies show that the efficiency of cell implants cannot be 
achieved without long‑term cell survival and cell‑con‑
ditioned culture medium, suggesting an essential role 
of secreted paracrine factors (Bi et al., 2007). The para‑
crine hypothesis not only includes secreted soluble fac‑
tors, but also extracellular vesicles such as exosomes, 
which contain similar content and elicit similar bio‑
logical activity to the stem cells (Camussi et al., 2013). 
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Exosomes are nanometer‑sized vesicles with a unique 
morphology, bilayer membrane protein, and lipid com‑
position, and are actively secreted into the extracel‑
lular space under normal and pathological conditions 
(Mincheva‐Nilsson et al., 2016). Recent data suggest 
that exosomes link stem cells to the neighboring dis‑
eased or damaged cells and shuttle protein, bio‑active 
lipid, and nucleic acid cargos into the recipient cells 
(Ratajczak et al., 2006). This process subsequently in‑
duces functional and phenotypic changes in the recip‑
ient cells.
The advantages of exosomes over cell‑therapy, and 
their similar function to cells (e.g., stem cells), pave the 
way for the clinical application of stem cell secreted 
exosomes. Stem cell derived exosomes have been isolat‑
ed and characterized from cell culture supernatants of 
several stem cell types, namely human neuronal stem 
cells (Drago et al., 2013). Despite the fact that secret‑
ed exosomes from a variety of cell types exhibit some 
shared contents, they also express distinctive mole‑
cules that identify their producer cells (Taylor et al., 
2011). Therefore, characterizing stem cell derived exo‑
somes with different sources will broaden the knowl‑
edge of their application in paracrine therapy, and will 
offer the opportunity to find promising therapeutic ap‑
proaches. In this study, we aimed to characterize exo‑
somes derived from human amniotic fluid (hAF) stem 
cells. Based on several previous studies demonstrating 
that stem cells constitute the majority of human amni‑
otic fluid, we speculated that exosomes isolated from 
hAF contain a high percentage of stem cell derived exo‑
somes (De Coppi et al., 2007; Dev et al., 2012; Yang et al., 
2013; Dziadosz et al., 2016). We also used SH‑SY5Y(Wal‑
ton et al., 2004; Ferlemann et al., 2017) and BE(2)‑M17 
(Andres et al., 2013; Ross et al., 2015), which are two 
well‑known neuronal models, to explore characteris‑
tics of their exosomes and to further understand and 
explore neurodifferentiation and neurobiology. In ad‑
dition, we used different sources to compare yield and 
purity of various exosome isolation methods.
METHODS
Cell culture and sample collection
SH‑SY5Y and BE(2)‑M17 are human neuroblastoma 
cell lines that are commonly used for modelling neu‑
rodegenerative diseases, and for studying basic mech‑
anisms in neuroscience. SH‑SY5Y and BE(2)‑M17 cell 
lines were obtained from Ege University (Department 
of Medical Biology, İzmir, Turkey) and Pasteur Institute 
of Iran, respectively. The cells were maintained in a 1:1 
mixture of Eagle’s minimum essential medium (EMEM) 
(ATCC, Cat. No. 30‑2003) and F12 medium (Merck, Cat. 
No. M4655) supplemented with 10% fetal bovine serum 
(FBS) (Gibco, Cat. No. 11573397), 100 U/mL penicillin, 
and 100 mg/mL streptomycin (Merck, Cat. No. P4333) 
and incubated at 37°C in 5% CO2. hAF samples, contain‑
ing stem cells and stem cell derived exosomes, were 
collected from patients recruited for genetic tests at 
the Avicenna Clinic (Tabriz, Iran) during the fifteen and 
sixteen weeks of pregnancy. Samples were collected 
following written informed consent, and approval by 
the Tabriz University of Medical Sciences Ethics Com‑
mittee (no. 5/D/72903). 
Exosome harvest
For all experiments, cells were cultured in 1:1 mix‑
ture of EMEM and F12 medium 10% FBS with defined 
cell density (4×10E5 cell/ml) to yield a confluent mono‑
layer of each cell line. Next, the supernatant was re‑
placed with EMEM supplemented with serum, which 
was free of exosomes (i.e., exosome depleted serum) 
(Gibco Cat. No. A2720801) for 48 h. After 48 h, the con‑
ditioned medium was collected and subjected to Exo‑
some isolation methods.
Exosome isolation
Ultracentrifugation
A two‑step centrifugation was carried out to obtain 
exosomes from the collected conditioned media (from 
≈ 16×10E6 cell, 20 ml)/hAF (18 ml). First, the media was 
centrifugation for 30 min at 48298 × g to dispose of de‑
bris and cell residues. Next, the supernatant was fil‑
tered through a 0.22 µm filter (Millipore Sigma). Then, 
ultracentrifugation (60 min at 584401 × g) was used on 
the filtered supernatant to pellet the exosomes. The 
pelleted exosome was subsequently re‑suspended in 
1 ml phosphate buffered saline (PBS). All ultracentrif‑
ugation steps were performed using the Beckman Opti‑
ma TLX Ultracentrifuge (CA, USA) at 4°C.
Exosome isolation kit 
Exosomes were isolated from the collected condi‑
tioned media (from ≈ 16×10E6 cell, 20 ml)/hAF (18 ml) 
using the ExoQuick exosome precipitation kit (System 
Biosciences, Cat. No EXOQ20A‑1), following the man‑
ufacturer’s instructions. The ExoQuick kit contains 
a nondenaturing water‑soluble polymer which, similar 
to a high salt concentration, can precipitate exosomes. 
Briefly, cultured conditioned media or collected amni‑
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otic fluid were mixed with ExoQuick reagent and then 
incubated for at least 1 h at 4°C. Then, exosomes were 
pelleted using low speed centrifugation (1500 × g) for 
10 min at 4°C. The exosome pellet was resuspended in 
1 ml PBS. 
Characterization of exosomes
Micro BCA protein assay 
The concentration of exosomal proteins was quan‑
tified using the Micro BCA protein assay (SMART micro 
BCA protein assay kit, Cat. No. 23235), according to the 
manufacturer’s instruction. In brief, 200 μl of isolated 
exosomes were incubated overnight at room tempera‑
ture with 200 μl lysis buffer (50 mM Tris‑HCL, 150 mM 
NaCl, 1% NP40 and 1 mM EDTA, one protease inhibitor 
tablet; Merck, Cat. No. 11697498001; PH=7.4). Following 
the incubation, exosomes were centrifuged for 5 min 
at 25155 × g and then the supernatant was extracted 
for the assay. 100 μl of Micro BCA protein assay work‑
ing solution was added to 100 μl exosome samples (un‑
known concentration) or standards (known concentra‑
tion), and then mixed thoroughly. Prepared samples 
were incubated at 37°C for 2 h, and absorbance was 
subsequently measured at 562 nm with a spectrome‑
ter. Next, we calculated a calibration curve by plotting 
the absorbance at 562 nm against the concentration of 
prepared standards. The unknown concentrations of 
the released exosomes were then determined from the 
calibration curve.
Flow cytometry 
Exosomal surface markers were analyzed using flow 
cytometry. First, exosomes were isolated as described 
above and then subjected to staining with antibodies 
that are specific to exosomal cluster of differentiation 
(CD) markers. Isolated exosomes were incubated for 1 h 
at 4°C with the following two antibodies: 4 μg of PE con‑
jugated anti CD63 monoclonal antibody (H5C6, Mouse 
/ IgG1, kappa) (eBioscience, Cat. No. 12‑0639‑42) and 
4 μg of FITC conjugated anti CD9 monoclonal antibody 
(SN4 C3‑3A2, Mouse/IgG1, kappa) (eBioscience, Cat. No. 
11‑0098‑42). Next, the samples were fixed with 5% para‑
formaldehyde, and the stained and fixed samples were 
subsequently diluted in 500 μl of filtered PBS and FACS 
buffer was added. To reduce the impact of nonspecif‑
ic binding to exosomes, we also had staining with an 
isotype control targeting irrelevant antigen. Flow cy‑
tometry data were acquired using a BD FACSCalibur (BD 
Biosciences) and analyzed using the FlowJo Software.
SDS PAGE and Western blot
Isolated exosomes (derived from the aforementioned 
ultracentrifugation protocol) were submitted to a western 
blotting analysis to examine exosomal surface markers. 
Exosome samples (derived from cell/hAF) were lysed in 
500 μl of RIPA extraction buffer (Thermo Scientific, Cat. 
No. 89900) and one protease inhibitor tablet (Merck, Cat. 
No. 11697498001). Protein concentration was quantified 
by the SMART Micro BCA protein assay kit. Then, approx‑
imately 60 µg of total protein per sample was subjected 
to 12% sodium dodecyl sulfate–polyacrylamide gel elec‑
trophoresis (SDS‑PAGE) at a constant 60 V at room tem‑
perature for 2 h. Next, the separated proteins were blotted 
onto polyvinyl‑difluoride (PVDF) membrane (Merck, Cat. 
No. 3010040001) at a constant 150 mA for 1 h. Membranes 
were then blocked with 10 ml of 5% non‑fat dry milk (Mer‑
ck, Cat. No. W236101) for 1 h at room temperature, and 
then washed and incubated with 5 μg of the corresponding 
primary antibodies (i.e., mouse monoclonal IgG1 targeting 
CD9 [Ts9], CD63 [Ts63] and D81 [M38], for Cat. No. 10626D, 
10628D, 10630D respectively; eBioscience) overnight at 
4°C. Lastly, the membrane was probed with 1 μg of horse‑
radish peroxidase‑conjugated secondary antibody, and 
Goat anti‑Mouse IgG Fc Secondary Antibody (eBioscience, 
Cat. No. A16084). Protein detection was carried out by ex‑
posing the membrane to an enhanced chemiluminescence 
(ECL) western blotting detection system (INTAS Advanced 
Fluorescence Imager, INTAS Science Imaging).
Dynamic light scattering
Exosomes were isolated from SH‑SY5Y and BE(2)‑M17 
conditioned medium and hAF via ultracentrifugation. 
Next, to estimate the exosome’s diameter distribution, 
we performed a dynamic light scattering (DLS) analysis 
on the isolated exosomes. The mean hydrodynamic di‑
ameter of exosomes was calculated by fitting a Gauss‑
ian function to the measured size distribution. Prior 
to the measurements, exosome samples were shaken at 
4°C for 10 min to avoid possible inter‑particle interac‑
tion and aggregation. About 500 μl of each sample was 
added to a cuvette and DLS measurements were con‑
ducted at 25°C using a Zetasizer Nano ZS90 (Malvern 
Instruments, UK). The sample temperature was equili‑
brated with room temperature for 10 min before each 
measurement. Light scattering was recorded for 10 s. 
 Statistical analysis
Differences between groups were analyzed by means 
of a Student’s t‑test or one‑ way ANOVA using Graph 
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Pad Prism 6.01. A p value of 0.05 (one‑tailed) or less was 
considered to be statistically significant. All values are 
presented as mean ± SD (three independent repeat).
RESULTS
Exosomal yield varies with isolation method but 
not with the cell passage’s number
Exosomal yield using different isolation methods 
was defined as the concentration of exosomal pro‑
teins. There was a significant difference between the 
two isolation methods in terms of exosomal yield, such 
that higher yield was found for the ultracentrifuga‑
tion isolation method as compared to commercial re‑
agents. The protein concentration of isolated exosomes 
via ultracentrifugation/reagent method for SH‑SY5Y, 
BE(2)‑M17 and hAF is as follow: 818.5± 75.9/139.6±29.4, 
223.7±47/106.6±10.3, and 558.9±53.8/352.7±32.8 (see 
Fig. 1). Given these results, we chose ultracentrifugation 
as an isolation method for the rest of the experiments.
Exosomes were isolated from the conditioned me‑
dium of SH‑SY5Y and BE(2)‑M17 cell cultures at vari‑
ous passage numbers (i.e., P2, P3, P4, P5 and P6) using 
ultracentrifugation. Of note, the cell passage for cell 
lines were designated as P1 upon arrival from the cor‑
responding cell bank. Then, the concentration of pro‑
duced exosomes was quantified via Micro BCA protein 
assay. We found that exosomal protein concentration, 
which reflects exosome production rate, did not sig‑
nificantly differ between the cell passage numbers 
(p>0.05, see Fig. 2). This experiment was performed in 
triplicate. 
hAF /SH‑SY5Y, BE(2)‑M17 cells exosomal surface 
markers: CD9, CD63
The presence of CD63 and CD9 on the surface of exo‑
somes derived from SH‑SY5Y and BE(2)‑M17 cells and 
hAF was confirmed by flow cytometry (Fig. 3A). To bet‑
ter characterize the exosomes derived from different 
sources (i.e., SH‑SY5Y and BE(2)‑M17 cells and hAF), we 
performed a flow cytometry‑based evaluation of CD9 
and CD63 markers. Flow cytometry results showed that 
exosomes derived from all three tested sources (i.e., 
SH‑SY5Y and BE(2)‑M17 cells and hAF) were positive for 
all investigated markers. Further, we found less CD63 
and CD9 in SH‑SY5Y and BE(2)‑M17 cells (p<0.0001) and 
CD9 (p<0.0001) as compared to in hAF derived exosomes 
(Fig. 3B).
Immunoblotting confi rms fl ow cytometry results
To confirm the flow cytometry results, we probed 
for CD63 and CD9 markers using western blot analysis. 
Protein lysates were prepared from the isolated exo‑
somes (i.e., SH‑SY5Y and BE(2)‑M17 cells and hAFs sam‑
ple). In accordance with the results obtained by flow 
cytometry (Fig. 3), we detected expression of both CD63 
and CD9 in 60 μg of protein lysates. Of note, exosomes 
were isolated via the ultracentrifugation method and 
lysed with RIPA buffer. In addition to these markers, we 
tested protein lysates of exosome samples for the ex‑
pression of another well‑known exosome marker, CD81. 
Results showed the expression of this protein marker 
in all samples (i.e., SH‑SY5Y, BE(2)‑M17, and hAF; see 
Fig. 4). Anti‑CD63 staining showed stronger expres‑
sion of CD63 in hAF samples as compared to the other 
Fig.  1. Q uantitative comparison between diff erent exosome isolation 
methods. Note that ultracentrifugation was associated with higher exo‑
somal yield as compared to polymer based precipitation. The y axis 
shows total protein concentration, as measured by a Micro BCA protein 
assay. Statistical analyses were performed using a one‑way ANOVA, (n=5). 
****p<0.0001, **p=0.0016.
Fig. 2. Cell culture passage number was not associated with diff erences 
in exosomal production rate. Note that no diff erence in exosomal pro‑
duction rate between passage numbers P2, P3, P4, P5, P6. ****p<0.0001, 
**p=0.0016.
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Fig. 3. Flow cytometry detection of exosomal surface markers. (A) Flow cytometry analysis showed the expression of both exosomal markers (i.e., CD9 and 
CD63) on the surface of exosomes derived from all three samples (i.e., SH‑SY5Y, BE(2)‑M17, and hAFs). (B) Comparison of mean fl uorescent intensity (MFI) 
for all three samples. Results show higher expression of CD63 expression on the surface of exosomes derived from hAF than those derived from both 
SH‑SY5Y and BE(2)‑M17 cells. **p=0.002, ****p<0.0001, n=3.
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two cell lines (i.e., SH‑SY5Y and BE(2)‑M17), which was 
consistent with the fluorescent intensity analysis via 
flow cytometry. Similarly, we found slightly higher (not 
significantly different) CD9 expression in hAF derived 
exosomes compared to SH‑SY5Y and BE(2)‑M17 cells. 
However, CD81 was detected equally across all three 
samples (i.e., SH‑SY5Y, BE(2)‑M17, hAF).
Physical characterization of exosomes by DLS
Sample size distribution of hAF‑cell derived exo‑
somes was measured using DLS. We found that aver‑
age exosome diameter was 54.33±20.35, 49.78± 3.43, 
21.44±6.11, respectively, for isolated exosomes from 
hAF, SH‑SY5Y, and BE(2)‑M17 (Table I). As shown in 
Fig. 5, hAF‑cell derived exosomes formed a bell‑shaped 
size distribution profile. The size distribution profiles 
were similar for exosomes from the aforementioned 
sources, with a polydispersity index ranging from 0.433 
to 0.483, which is indicative of homogeneous exosome 
preparations (Table I).
DISCUSSION
The last decade has witnessed a growing number 
of research studies on exosomes. Exosomes are con‑
sidered to be important intercellular communicators 
that are capable of transporting and transferring all 
types of biomolecules. This capacity makes exosomes 
valuable tools for diagnostic purposes, or as potential 
nanocarriers (Soria et al., 2017). A large number of 
studies have been conducted on exosomes, and these 
studies have answered many questions regarding the 
biogenesis, characteristics, functions, and physiolog‑
ical role of exosomes. However, their role and impor‑
tance in degenerative diseases – and in particular, 
neurodegenerative disease – is yet to be completely 
understood (Quek et al., 2017). Given that exosomes 
protect their cargoes from degradation, screening of 
exosomes, particularly in cerebrospinal fluid (CSF), 
may offer a diagnostic tool and may provide insights 
into pathogenic processes in the central nervous sys‑
tem (CNS), which is typically difficult to access. On 
the other hand, the ability of exosomes to cross the 
blood‑brain barrier and to pass into CSF highlights 
their potential application as drug delivery vehicles 
targeting the CNS (Jan et al., 2017). Recently, it has 
been shown that exosomes secreted from neuronal 
stem cells play a critical role in the CNS niche (Lu‑
arte et al., 2016). These results highlight the merit of 
neuronal stem cell derived exosomes as diagnostic 
tools and therapeutic delivery vehicles, and demand 
more research in this field. In this study, we focused 
on two well‑known neuronal models (i.e., SH‑SY5Y 
and BE(2)‑M17 (Alberio et al., 2012)), as well as, human 
amniotic fluid stem cell, and characterized exosomes 
derived from each source. A large number of studies 
have reported that the majority of cells in human am‑
niotic fluid are stem cells, and based on these results, 
we speculated that the majority of exosomes are from 
stem cells (Dev et al., 2012). In addition, the present 
study highlighted some technical points regarding 
isolation method using three different sources.
Our data showed that exosome yield varies with 
isolation method, but not with cell passage. Using two 
different isolation methods (i.e., ultracentrifugation 
and commercial reagent) on three different exosomal 
sources (including two neuronal cell models and hAF), 
we showed that exosomal yield is higher following ul‑
tracentrifugation as compared to commercial reagent. 
These results are in agreement with Gheinani et al. 
(2018), who used urinary samples to demonstrate that 
the ultracentrifugation method produced the highest 
exosomal yield. However, the authors also noted high 
variability in this method. Nonetheless, it is notewor‑
thy to mention that the ultracentrifugation method 
Fig. 4. Western blot analysis of CD63, CD9, and CD81 expression on the sur‑
face of exosomes. Data showed higher expression of CD63 and CD9 in hAF 
samples as compared to exosomes derived from SH‑SY5Y and BE(2)‑M17 
lines. Expression levels for CD81, in contrast, did not signifi cantly diff er 
between samples, using an equal amount of protein lysates from samples.
Table I. Physical characterization of exosomes derived from human neuro‑
blast cell lines and hAF.
Exosome 
source Size (nm)
Polydispersity 
Index (PdI)
Z‑potential 
(mV)
hAF 54.33 ± 20.35 0.471 ‑23.6 ± 6.42
SH‑SY5Y 49.78 ± 23.43 0.483 ‑23.6 ± 6.42
BE(2)‑M17 21.44 ± 6.11 0.433 ‑23.6 ± 6.42
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Fig. 5. Size distribution of exosomes derived from different sources. Of note, exosomes were isolated using the ultracentrifugation method. Each curve 
shows means ± SD from three replicates. 
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has not been proven to be an ideal method to isolate 
exosomes from serum. For example, albumin contam‑
ination was shown to be higher with ultracentrifuga‑
tion compared to commercial reagents and size exclu‑
sion chromatography (Baranyai et al., 2015; Helwa et 
al., 2017). Our results also demonstrate that the effect 
of cell passage number can be ignored, as we observed 
no significant differences between exosomal produc‑
tion rate for different passage numbers. These null 
results are in agreement with another study that as‑
sessed the potential impact of cell passage number on 
mesenchymal stem cell exosome production. In that 
study, nanoparticle tracking analysis was used, and 
no difference was observed between different passage 
numbers (Patel et al., 2017). 
Further, immunoblot and Flow cytometry analysis 
revealed that all samples (i.e., SH‑SY5Y, BE(2)‑M17, 
and hAF) were enriched with CD63 (Logozzi et al., 
2009), CD9 (Yoshioka et al., 2013) and CD81 (Welker et 
al., 2012), which are protein markers associated with 
exosomes,. Our data also show uniform expression 
of CD81 in exosomes derived from all sources inves‑
tigated in this study. However, there was higher ex‑
pression of CD9 and CD63 in exosomes derived from 
hAF as compared to those derived from SH‑SY5Y and 
BE(2)‑M17. 
The expression of conventional exosome CD mark‑
ers (CD63, CD81, CD9) has shown for the first time by 
Balbi et al. (2017) who performed fluorescence‐ac‑
tivated cell sorting (FACS) analysis on conditioned 
medium from hAFs. In their study, they kept hAFs in 
culture to enrich the medium and isolate the extra‑
cellular vesicles. In the present study, in contrast, we 
isolated exosomes directly from hAF without manip‑
ulating conditions to obtain in vivo stem cell secret‑
ed exosomes and characterize them by determining 
protein markers. This approach insight to naturally 
occurring exosomes in human fluids. Nonetheless, 
results of the present study together with Balbi et 
al. provide in vivo and in vitro evidence that secreted 
exosomes from hAFs express conventional exosome 
markers, including CD63, CD9, and CD81. In addition, 
a comparison of hAF derived exosomes with two es‑
tablished human neuronal cell models showed higher 
expression of these markers in hAF.
Physical characterization via DLS showed homog‑
enous size distribution for exosomes isolated using 
ultracentrifugation for all three samples. The ob‑
served exosomal diameter ranged on average between 
20–55 nm, which is in agreement with prior research 
on exosome diameter range. In another study done by 
Park et al. (2015) SH‑SY5Y derived exosomal diame‑
ter was measured using dynamic light‑scattering and 
showed a diameter range of 50–170 nm.
CONCLUSION 
Although a large number of research studies have 
focused on functional analysis and characterization of 
exosomes secreted by different stem cells, few studies 
have reported on hAF derived exosomes. Our results 
may offer meaningful initial insights on the charac‑
terization of hAF derived exosomes for future thera‑
peutic applications. Indeed, hAF derived exosomes can 
be easily isolated from left over samples of amniotic 
fluid from amniocentesis, or during cesarean delivery 
without ethical concern. On the other hand, charac‑
terizing SH‑SY5Y and BE(2)‑M17 derived exosomes as 
well‑known neuronal models will help to advance our 
understanding of neurobiology and neuronal differen‑
tiation, and develop new therapeutic approaches for 
neurodegenerative disease. In addition, major chal‑
lenges need to be addressed to bring exosome technol‑
ogy into clinic, such as developing efficient standard‑
ized isolation and purification methods. 
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